Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis-Reference-Cited by-同舟云学术

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Published:2023-11 Issue:5 Volume:79 Page:1110-1120
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Sanyal Arun J.,Ratziu Vlad,Loomba Rohit,Anstee Quentin M.^ORCID,Kowdley Kris V.,Rinella Mary E.,Sheikh Muhammad Y.,Trotter James F.,Knapple Whitfield,Lawitz Eric J.^ORCID,Abdelmalek Manal F.,Newsome Philip N.^ORCID,Boursier Jérôme,Mathurin Philippe,Dufour Jean-François,Berrey M. Michelle,Shiff Steven J.,Sawhney Sangeeta,Capozza Thomas^ORCID,Leyva Rina,Harrison Stephen A.,Younossi Zobair M.

Publisher

Elsevier BV

Subject

Hepatology

Reference42 articles.

1. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease;Rinella;Hepatology,2023

2. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease;Estes;Hepatology,2018

3. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

4. Nonalcoholic steatohepatitis;Suzuki;Annu Rev Med,2017

5. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials;Sanyal;Hepatology,2019

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation;Redox Biology;2024-10

2. Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches;Cureus;2024-09-10

3. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

4. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches;International Journal of Molecular Sciences;2024-08-10

5. The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications;Acta Pharmaceutica Sinica B;2024-08